Verificando…
Traducido automáticamente. Dosis y advertencias: consulta el original en inglés. Leer en inglés
Inicio / Registrado en Nigeria / Bioptan Eyedrops

Bioptan Eyedrops

NAFDAC Reg. No. B4-3909 Estupefaciente

Registrado en NAFDAC. Registro activoAs of 1 November 2026 · synced automatically from official sources.
Producto
Bioptan Eyedrops
Número NAFDAC
B4-3909
Principio activo
Bimatoprost
Dosis
0.03%
Forma
Colirio
Tamaño del envase
1 x 5 mL (in LDPE bottle)
Fabricante
No Constan
Solicitante (titular)
Korlyns Pharmaceuticals Ltd
Approved
26 Apr 2023
Estado
Activo Ver en NAFDAC ↗
Registro válido hasta
25 Apr 2028
Alertas de la OMS
No se ha encontrado ninguno
Informes de la comunidad
Ninguno
Tiempos comprobados
0

Pero sobre el medicamento, Bimatoprost: uses, dosage and brands worldwide

Lo que encontramos

  • Bioptan Eyedrops is on the NAFDAC register with an active registration (B4-3909). A valid number alone does not prove a pack is genuine — counterfeiters copy real numbers, so also check the expiry date, seal and print quality.

Generado automáticamente a partir del registro NAFDAC, QUIÉN alerta y los datos de la comunidad a partir de hoy. Este no es un consejo médico. Siga siempre a su médico o farmacéutico.

How to use Bioptan Eyedrops

Lo que dice el prospecto oficial. Si te lo recetó un médico, sigue la receta. Si el prospecto de tu caja es distinto, manda el de tu caja.

Para quién es

Bimatoprost ophthalmic solution 0.03% is indicated for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension. Bimatoprost ophthalmic solution 0.03% is a prostaglandin analog indicated for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension. ( 1 )

Cómo tomarlo y con qué frecuencia
  • The recommended dosage is one drop in the affected eye(s) once daily in the evening
  • Bimatoprost ophthalmic solution 0.03% should not be administered more than once daily since it has been shown that more frequent administration of prostaglandin analogs may decrease the intraocular pressure lowering effect
  • Reduction of the intraocular pressure starts approximately 4 hours after the first administration with maximum effect reached within approximately 8 to 12 hours
  • Bimatoprost ophthalmic solution 0.03% may be used concomitantly with other topical ophthalmic drug products to lower intraocular pressure
  • Si se usa más de un medicamento oftálmico tópico, los fármacos deben administrarse al menos con 5 minutos de diferencia.
  • One drop in the affected eye(s) once daily in the evening
Fortalezas en las que viene

Ophthalmic solution containing bimatoprost 0.3 mg/mL. Ophthalmic solution containing 0.3 mg/mL of bimatoprost. ( 3 )

Infancia

Use in pediatric patients below the age of 16 years is not recommended because of potential safety concerns related to increased pigmentation following long-term chronic use.

Older adults

No overall clinical differences in safety or effectiveness have been observed between elderly and other adult patients.

While you are taking it
  • Potential for Pigmentation Advise patients about the potential for increased brown pigmentation of the iris, which may be permanent
  • Also inform patients about the possibility of eyelid skin darkening, which may be reversible after discontinuation of bimatoprost ophthalmic solution 0.03%
  • Potential for Eyelash Changes Inform patients of the possibility of eyelash and vellus hair changes in the treated eye during treatment with bimatoprost ophthalmic solution 0.03%
  • These changes may result in a disparity between eyes in length, thickness, pigmentation, number of eyelashes or vellus hairs, and/or direction of eyelash growth. …
Talk to a doctor first if
  • Bimatoprost ophthalmic solution 0.03% is contraindicated in patients with hypersensitivity to bimatoprost or to any of the ingredients [see Adverse Reactions ]
  • Hypersensitivity
Warnings

Pigmentation : Pigmentation of the iris, periorbital tissue (eyelid) and eyelashes can occur. Iris pigmentation is likely to be permanent. ( 5.1 ) Eyelash Changes : Gradual change to eyelashes including increased length, thickness and number of lashes. Usually reversible. ( 5.2 ) 5.1 Pigmentation Bimatoprost ophthalmic solution has been reported to cause changes to pigmented tissues. The most frequently reported changes have been increased pigmentation of the iris, periorbital tissue (eyelid) and eyelashes. Pigmentation is expected to increase as long as bimatoprost is administered. …

Posibles efectos secundarios

The following adverse reactions are described elsewhere in the labeling: • Pigmentation [see Warnings and Precautions (5.1) ] • Eyelash Changes [see Warnings and Precautions (5.2) ] • Intraocular Inflammation [see Warnings and Precautions (5.3) ] • Macular Edema [see Warnings and Precautions (5.4) ] • Hypersensitivity [see Contraindications (4) ] Most common adverse reaction (45%) is conjunctival hyperemia ( 6.1 ). To report SUSPECTED ADVERSE REACTIONS, contact Aurobindo Pharma USA, Inc. at 1-866-850-2876 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . …

Pregnancy and breastfeeding

8.1 Pregnancy Risk Summary There are no adequate and well-controlled studies of bimatoprost ophthalmic solution 0.03% administration in pregnant women. There is no increase in the risk of major birth defects or miscarriages based on bimatoprost postmarketing experience. …

If you take too much

No information is available on overdosage in humans. If overdose with bimatoprost ophthalmic solution 0.03% occurs, treatment should be symptomatic. In oral (by gavage) mouse and rat general toxicity studies, doses up to 100 mg/kg/day did not produce any toxicity. This dose expressed as mg/m 2 is at least 70 times higher than the accidental dose of one bottle of bimatoprost ophthalmic solution 0.03% for a 10 kg child.

Si olvidas una dosis

Tómala en cuanto te acuerdes, salvo que falte poco para la siguiente. En ese caso, sáltate la olvidada. Nunca tomes dos dosis a la vez para compensar. Revisa tu prospecto, porque algunos medicamentos son distintos.

From the official U.S. FDA label for this active ingredient. Your pack may have a different strength, so always read its leaflet. If a doctor prescribed it, follow the prescription. Ask a pharmacist if you are unsure. Label dated 2023-07-17.

Label for bimatoprost, the active ingredient registered with NAFDAC.

Check your pack of Bioptan Eyedrops

Add the expiry date on your pack for a full Trust Score.

O haz fotos de la caja
Te quedan 3 verificaciones gratis hoy Fuentes oficiales: FDA de EE. UU. · EMA (UE) · NAFDAC · alertas de la OMS

About Bioptan Eyedrops

What is in Bioptan Eyedrops?

Bioptan Eyedrops contains Bimatoprost (0.03%), as eye drops, according to its NAFDAC registration record.

Is Bioptan Eyedrops registered with NAFDAC?

Yes. Bioptan Eyedrops is listed on the NAFDAC register under registration number B4-3909, and its registration is active as of 1 November 2026.

Has Bioptan Eyedrops been flagged as fake or recalled?

No WHO falsified or substandard medical product alert currently matches Bioptan Eyedrops in our automatically synced alert list.

How can I check that my pack of Bioptan Eyedrops is genuine?

Run a free authenticity scan with the NAFDAC number B4-3909, your pack's expiry date and batch number to get a Trust Score, compare the pack with the NAFDAC record (ingredient, strength, form, manufacturer), and buy only from licensed pharmacies.

How do I take Bioptan Eyedrops?

Follow your prescription or the leaflet in your pack. The official label says: The recommended dosage is one drop in the affected eye(s) once daily in the evening. Bimatoprost ophthalmic solution 0.03% should not be administered more than once daily since it has been shown that more frequent administration of prostaglandin analogs may decrease the intraocular pressure lowering effect. Reduction of the intraocular pressure starts approximately 4 hours afte…

What is Bioptan Eyedrops used for?

Bimatoprost ophthalmic solution 0.03% is indicated for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension. Bimatoprost ophthalmic solution 0.03% is a prostaglandin analog indicated for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension. ( 1 ) (Summarised from the official U.S. FDA label for bimatoprost. Always follow your doctor or pharmacist.)

Patient reviews

–No reviews yet
5★
0
4★
0
3★
0
2★
0
1★
0
Have you used Bioptan Eyedrops? Share your experience to help other patients. Sign in to review

Reviews are personal experiences from PillVera users, not medical advice. Report side effects to your doctor and to NAFDAC.